Search
Reglitazar
go.drugbank.com/drugs/DB04971ExperimentalReglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
Categories: Heterocyclic Compounds, 1-RingCanfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Imisopasem manganese
go.drugbank.com/drugs/DB04976InvestigationalM40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
SP1049C
go.drugbank.com/drugs/DB04978Experimental[A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. … SP1049C is a novel anthracycline chemotherapeutic agent containing [doxorubicin] and two nonionic pluronic block copolymers.
Categories: Compounds used in a research, industrial, or household settingSynonyms: doxorubicin with pluronics F-127 and L-61, Doxorubicin HCl with pluronic L-61 and pluronic F-127CG7870
go.drugbank.com/drugs/DB04981InvestigationalIt is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
IGN311
go.drugbank.com/drugs/DB04988ExperimentalIGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
AP5346
go.drugbank.com/drugs/DB04992InvestigationalAP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.
AeroLEF
go.drugbank.com/drugs/DB05000InvestigationalAeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia … AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain.
PSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing. … PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes.
Peptide YY (3-36)
go.drugbank.com/drugs/DB05004InvestigationalPeptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Synonyms: PYY 3-36, PYY(3-36)